Incyte Corp

Quantli Newsdesk

· 18 days ago

Incyte delivered a strong second quarter with revenue increasing 38% to $1.67 billion, driven by robust growth across its commercial portfolio and a $246 million one-time benefit from Opzelura. The company raised its full-year sales guidance significantly, reflecting confidence in its expanding product portfolio and successful diversification beyond its flagship drug Jakafi.

Quantli Newsdesk

· 2 months ago

Incyte is acquiring Vega Therapeutics for $1.25 billion upfront to gain access to VGA039, a late-stage drug for severe von Willebrand disease. The deal aims to offset revenue losses from Jakafi's patent expiration in 2028, with analysts projecting the new drug could generate over $1 billion in annual sales by the early 2030s.

10-K

Quantli Newsdesk

· 4 months ago

Incyte delivered net income of $1.3 billion in 2025 versus $33 million in 2024, driven by a favorable Novartis royalty settlement and 20% total revenue growth to $5.1 billion. The company launched NIKTIMVO, expanded OPZELURA internationally, and strengthened its commercial portfolio ahead of JAKAFI's 2028 patent expiration.